Ypsomed Holding AG (YPHDF)
OTCMKTS · Delayed Price · Currency is USD
535.75
0.00 (0.00%)
At close: Jul 21, 2025
Bally's Revenue
In the fiscal year ending March 31, 2025, Ypsomed Holding AG had annual revenue of 748.87M CHF with 36.54% growth. Ypsomed Holding AG had revenue of 424.86M in the half year ending March 31, 2025, with 67.79% growth.
Revenue
748.87M CHF
Revenue Growth
+36.54%
P/S Ratio
7.78
Revenue / Employee
283.23K CHF
Employees
2,644
Market Cap
6.59B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 748.87M | 200.41M | 36.54% |
| Mar 31, 2024 | 548.46M | 51.00M | 10.25% |
| Mar 31, 2023 | 497.46M | 32.62M | 7.02% |
| Mar 31, 2022 | 464.84M | 61.19M | 15.16% |
| Mar 31, 2021 | 403.66M | 9.39M | 2.38% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
Ypsomed Holding AG News
- 9 months ago - Novo Nordisk (NVO) Partners with Ypsomed for Next-Gen Obesity Drug Delivery - GuruFocus
- 9 months ago - Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens - Seeking Alpha